The thesis

SEPN is a clinical-stage biotechnology company developing oral small molecule products for various diseases. The company has achieved 12011.0% year-over-year revenue growth, with a gross margin of 9942.0%. The conviction tier is medium at 48/100, and the analyst consensus rating is buy. This setup is interesting due to the significant revenue growth and high gross margin, despite a negative net margin of -4988.0% and a P/E ratio of -43.4x,

Why now

The current macro moment, with China's chip tool push and the US-China squeeze, creates an uncertain environment for biotech companies like SEPN. The company's high revenue growth and unique product pipeline make it compelling to watch, especially with a DCF intrinsic value of $-21,

What to watch

The company's future revenue growth and net margin performance will be key indicators to watch over the next 1-3 quarters. Additionally, any updates on the PTH1R Program and other product pipeline developments will be crucial in confirming or denying the thesis.

Key risks

Valuation risk is a significant concern due to the negative P/E ratio and high revenue growth, which may not be sustainable. Execution risk is also a factor, as the company's products are still in the clinical-stage development phase. Additionally, macro risk from the US-China trade tensions and the Middle East war may impact the company's operations and funding,